



Structure and Function of the Human Breast L2

Robert D. Cardiff, M.D., Ph.D

Welcome Trust

△ TRUST

Dr. V. Seewaldt

December 8, 2021

Due Diligence

1. Size of TDLU

- a) RDC and ADB
- b) Jindal et al
- c) Kinsler et al

2. How many Epithelial Cell types?



TDLU: SIZE AND NUMBER

Kensler KH, Liu EZF, Wetstein SC, Onken AM, Luffman CI, Baker GM, Collins LC, Schnitt SJ, Bret-Mounet VC, Veta M, Pluim JPW, Liu Y, Colditz GA, Eliassen AH, Hankinson SE, Tamimi RM, Heng YJ. **Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk.** *Cancer Epidemiol Biomarkers Prev.* 2020 Nov;29(11):2358-2368. doi: 10.1158/1055-9965.EPI-20-0723. Epub 2020 Sep 11. PMID: 32917665; PMCID: PMC7642012.

Table 2. Quantitative TDLU measures and breast cancer risk factors among 1,083 controls.

	<i>n</i>	Median TDLU span (μm)	TDLU counts/ mm^2	Median acini counts/TDLU	Median TDLU area (mm^2)
Age at BBD biopsy					
<40 years	244	0.56 (0.55–0.58)	0.48 (0.44–0.52)	7.56 (7.11–8.04)	0.11 (0.10–0.11)
40–49 years	431	0.52 (0.51–0.53)	0.49 (0.46–0.51)	7.52 (7.18–7.87)	0.09 (0.09–0.10)
50–59 years	272	0.47 (0.45–0.48)	0.43 (0.40–0.46)	5.32 (5.02–5.64)	0.07 (0.07–0.07)
≥ 60 years	136	0.46 (0.44–0.47)	0.38 (0.34–0.42)	4.33 (3.99–4.71)	0.07 (0.06–0.07)
<i>P</i>		<0.001	<0.001	<0.001	<0.001
BBD histologic subtype					
Nonproliferative	303	0.49 (0.48–0.51)	0.43 (0.40–0.46)	6.40 (6.05–6.78)	0.08 (0.08–0.09)
Proliferative without atypia	625	0.51 (0.50–0.52)	0.46 (0.44–0.48)	6.36 (6.12–6.62)	0.09 (0.08–0.09)
Atypical hyperplasia	155	0.51 (0.50–0.53)	0.48 (0.44–0.53)	6.86 (6.33–7.43)	0.09 (0.08–0.10)
<i>P</i>		0.06	0.14	0.25	0.04
Body size at ages 5–10 years					
Level 1	308	0.51 (0.50–0.53)	0.46 (0.43–0.49)	6.58 (6.22–6.97)	0.09 (0.08–0.09)
Level 1.5 to 2	276	0.51 (0.50–0.52)	0.45 (0.42–0.48)	6.66 (6.27–7.07)	0.09 (0.08–0.09)
Level ≥ 2.5	353	0.50 (0.49–0.51)	0.46 (0.44–0.49)	6.12 (5.80–6.45)	0.08 (0.08–0.09)
<i>P</i>		0.44	0.84	0.07	0.10
BMI (kg/m^2)					
<25	612	0.51 (0.50–0.52)	0.45 (0.43–0.47)	6.52 (6.26–6.78)	0.09 (0.08–0.09)
25 to <30	288	0.50 (0.49–0.52)	0.45 (0.42–0.48)	6.62 (6.24–7.01)	0.08 (0.08–0.09)
≥ 30	169	0.51 (0.49–0.52)	0.48 (0.44–0.52)	5.90 (5.47–6.36)	0.08 (0.08–0.09)
<i>P</i>		0.88	0.44	0.04	0.34

MOUSE-HUMAN MAMMARY EPITHELIUM sc-RNA-Seq




Journal of Mammary Gland Biology and Neoplasia (2021) 26:43–66
<https://doi.org/10.1007/s10911-021-09486-3>

ORIGINAL PAPER




Characterization of Gene Expression Signatures for the Identification of Cellular Heterogeneity in the Developing Mammary Gland

Samantha Henry^{1,2} · Marygrace C. Trousdell¹ · Samantha L. Cyril¹ · Yixin Zhao¹ · Mary. J. Felgman¹ · Julla M. Bouhuls³ · Dominik A. Aylard⁴ · Adam Slepel¹ · Camila O. dos Santos¹



COMPUTER RECONSTRUCTION by Going



Subgross and Functional Histology





FIGURE 8

Diagram of Terminal Ductal Lobular Unit (TDLU). ETD: Extralobular Terminal Duct. ITD: Intralobular Terminal Duct, which is the axial core of the lobule. A: Acinus (or alveolus or ductule).





Subgross and Functional Histology






FIGURE 8

Diagram of Terminal Ductal Lobular Unit (TDLU). ETD: Extralobular Terminal Duct. ITD: Intralobular Terminal Duct, which is the axial core of the lobule. A: Acinus (or alveolus or ductule).







Type 1




Type 2



Type 3




Type 4



THE FOUR “TYPES” OF TDLU

JINDAL and SCHEDIN




N=112 volunteers


> NPJ Breast Cancer. 2020 Oct 16;6:55. doi: 10.1038/s41523-020-00196-3. eCollection 2020.


Characterization of weaning-induced breast involution in women: implications for young women's breast cancer

Sonal Jindal ^{1 2}, Jayasri Narasimhan ¹, Virginia F Borges ^{# 3 4}, Pepper Schedin ^{# 1 2 3 4}


EX10-0218DV-12-TDLU 3-HE-10X-
RDC








Krt8/18




SMA


EX10-0218DV-3-TDLU1-ER-20X-RDC




EX10-0218DV-3-TDLU1-PR-20X-RDC



EX10-0218DV-12-TDLU1-ER-10X-RDC





The “Menstrual Cycle”







Human Menstrual Cycle

Human Menstrual Cycle






Loose CT


100um

ST12-0010-PANEL-HE-KI-ER-PR- 20X-RDC


H&E




KI67




ER



PR







Loose CT



100um

How many types of ME Cells exist?





NON- ME
Cells Stroma


The evolutionary conserved basis of murine and human breast epithelial identity. (A) UMAP plot showing the distribution of epithelial cells identified to be present in murine and human breast tissue datasets (mhEC). (B) Cell abundance distribution of murine (Protocol #1 and Protocol #2, mEC) and human (HEC, NgNC Ind #5, NgNC Ind #6, NgNC Ind #7) breast tissue datasets. (C) Dot plot and dendrogram branching showing the average and percentage of expressed genes that distinguished and classified clusters of epithelial cell lineages present in murine and human breast tissue datasets. (D) UMAP plot illustrating the lineage identity of epithelial cell lineages present in murine and human breast tissue datasets.

Normal cell-type epigenetics and breast cancer classification: a case study of cell mixture-adjusted analysis of DNA methylation data from tumors

[Eugene Andrés Houseman¹](#), [Tan A Ince²](#)



DNA/CK/CD3(T cells)/CD20(B cells)




Dr. Hidetoshi Mori

100µm



DNA/CK/CD8(CTL cells)/CD68(Macrophage)




Dr. Hidetoshi Mori

100µm


60.57, 562.15 µm
1.38, 0.15, 0, 0

**PLASMA CELLS PRODUCE
IgA and IgM**




100um

**PLASMA CELLS PRODUCE
IgA and IgM**



LACTATION subgross



MAMMARY NATURAL HISTORY:

Ageing




FIGURE 11

Diagram illustrating the natural history of a normal human mammary lobule which progresses from premenarche (upper left) through the reproductive years (bottom left and bottom right), to post-menopausal (senescent) atrophy (upper right).








FIGURE 11
 Diagram illustrating the natural history of a normal human mammary lobule which progresses from premenarche (upper left) through the reproductive years (bottom left and bottom right), to post-menopausal (senescent) atrophy (upper right).


Elderly



Post-menopausal



Young Adult



Reproductive






Table 2. Quantitative TDLU measures and breast cancer risk factors among 1,083 controls.

	<i>n</i>	Median TDLU span (μm)	TDLU counts/ mm^2	Median acini counts/TDLU	Median TDLU area (mm^2)
Age at BBD biopsy					
<40 years:	244	0.56 (0.55-0.58)	0.48 (0.44-0.52)	7.56 (7.11-8.04)	0.11 (0.10-0.11)
40-49 years:	431	0.52 (0.51-0.53)	0.49 (0.46-0.51)	7.52 (7.18-7.87)	0.09 (0.09-0.10)
50-59 years:	272	0.47 (0.45-0.48)	0.43 (0.40-0.46)	5.32 (5.02-5.64)	0.07 (0.07-0.07)
≥ 60 years:	136	0.46 (0.44-0.47)	0.38 (0.34-0.42)	4.33 (3.99-4.71)	0.07 (0.06-0.07)
<i>p</i>		<0.001	<0.001	<0.001	<0.001



TCGA-01 TDLU 30 YO HI 3-HE-4X- psd-RDC1



BY POPULAR DEMAND:

WHAT ARE THE CHARACTERISTICS
OF THE
MAMMARY EPITHELIUM?

TDLU: SIZE AND NUMBER

Kensler KH, Liu EZF, Wetstein SC, Onken AM, Luffman CI, Baker GM, Collins LC, Schnitt SJ, Bret-Mounet VC, Veta M, Pluim JPW, Liu Y, Colditz GA, Eliassen AH, Hankinson SE, Tamimi RM, Heng YJ. **Automated Quantitative Measures of Terminal Duct Lobular Unit Involution and Breast Cancer Risk.** *Cancer Epidemiol Biomarkers Prev.* 2020 Nov;29(11):2358-2368. doi: 10.1158/1055-9965.EPI-20-0723. Epub 2020 Sep 11. PMID: 32917665; PMCID: PMC7642012.

Table 2. Quantitative TDLU measures and breast cancer risk factors among 1,083 controls.

	<i>n</i>	Median TDLU span (μm)	TDLU counts/ mm^2	Median acini counts/TDLU	Median TDLU area (mm^2)
Age at BBD biopsy					
<40 years	244	0.56 (0.55–0.58)	0.48 (0.44–0.52)	7.56 (7.11–8.04)	0.11 (0.10–0.11)
40–49 years	431	0.52 (0.51–0.53)	0.49 (0.46–0.51)	7.52 (7.18–7.87)	0.09 (0.09–0.10)
50–59 years	272	0.47 (0.45–0.48)	0.43 (0.40–0.46)	5.32 (5.02–5.64)	0.07 (0.07–0.07)
≥ 60 years	136	0.46 (0.44–0.47)	0.38 (0.34–0.42)	4.33 (3.99–4.71)	0.07 (0.06–0.07)
<i>P</i>		<0.001	<0.001	<0.001	<0.001
BBD histologic subtype					
Nonproliferative	303	0.49 (0.48–0.51)	0.43 (0.40–0.46)	6.40 (6.05–6.78)	0.08 (0.08–0.09)
Proliferative without atypia	625	0.51 (0.50–0.52)	0.46 (0.44–0.48)	6.36 (6.12–6.62)	0.09 (0.08–0.09)
Atypical hyperplasia	155	0.51 (0.50–0.53)	0.48 (0.44–0.53)	6.86 (6.33–7.43)	0.09 (0.08–0.10)
<i>P</i>		0.06	0.14	0.25	0.04
Body size at ages 5–10 years					
Level 1	308	0.51 (0.50–0.53)	0.46 (0.43–0.49)	6.58 (6.22–6.97)	0.09 (0.08–0.09)
Level 1.5 to 2	276	0.51 (0.50–0.52)	0.45 (0.42–0.48)	6.66 (6.27–7.07)	0.09 (0.08–0.09)
Level ≥ 2.5	353	0.50 (0.49–0.51)	0.46 (0.44–0.49)	6.12 (5.80–6.45)	0.08 (0.08–0.09)
<i>P</i>		0.44	0.84	0.07	0.10
BMI (kg/m^2)					
<25	612	0.51 (0.50–0.52)	0.45 (0.43–0.47)	6.52 (6.26–6.78)	0.09 (0.08–0.09)
25 to <30	288	0.50 (0.49–0.52)	0.45 (0.42–0.48)	6.62 (6.24–7.01)	0.08 (0.08–0.09)
≥ 30	169	0.51 (0.49–0.52)	0.48 (0.44–0.52)	5.90 (5.47–6.36)	0.08 (0.08–0.09)
<i>P</i>		0.88	0.44	0.04	0.34

Normal TDLU with Multiplex (INCE)




Figure 1

Expression of intermediate filaments and ER in normal human breast. Single and double IHC with immunoperoxidase (A–E, G, I, and K) and merged IHC images (F and J) of normal human FFPE sections are shown. (A) K7/18 (brown). (B) K18 (red) and K19 (brown). (C) K5/14 (brown). (D) CD10 (red) and K14 (brown). (E) K5/14 (brown) and SMA (red). (F) K18 (green) and K14 (red). Merged K14+K18+ appears yellow. (G) K5/14 (red) and ER (brown). We designated this population of cells K5/14/17+ because the tissue sections were not stained simultaneously with these markers. (H) Differentiation states of normal luminal epithelial cells, based on expression of ER and keratins. (I) Ki67 (brown) and K5/14 (blue). (J) ER (green) and Ki67 (red). (K) K18 (red) and Ki67 (brown). (L) Differentiation states of normal luminal epithelial cells, based on ER, keratins, and Ki67. Representative images were selected from multiple patient samples ($n = 36$). Original magnification, $\times 20$ (A); $\times 40$ (B); $\times 200$ (F); $\times 400$ (C, G, and I–K); $\times 600$ (D and E). See <http://sylvester.org/ince> for additional high-resolution images.

[J Clin Invest.](#) 2014 Feb 3; 124(2): 859–870.

Taxonomy of breast cancer based on normal cell phenotype predicts outcome

[Sandro Santagata](#),¹ [Ankita Thakkar](#),² [Ayse Ergonul](#),² [Bin Wang](#),² [Terri Woo](#),¹ [Rong Hu](#),^{3,4} [J. Chuck Harrell](#),⁵ [George McNamara](#),² [Matthew Schwede](#),⁶ [Aedin C. Culhane](#),⁶ [David Kindelberger](#),¹ [Scott Rodig](#),¹ [Andrea Richardson](#),¹ [Stuart J. Schnitt](#),⁷ [Rulla M. Tamimi](#),^{3,4} and [Tan A. Ince](#)²

Normal TDLU with Multiplex (INCE)





Figure 2

Expression of intermediate filaments, ER, AR, and VDR in normal human breast. Double IHC (A and J) and merged images (B, C, E–I, and K–M) of normal human breast FFPE sections...



Human Mammary Epithelium (TAN INCE)

Table 1

Cellular differentiation states in normal human breast lobules

Cell type		ER	AR	VDR	K5/14/17	Ki67	Cld-4	K7/8/18	CD10/SMA/p63
Luminal									
L1 (HR0)	Ki67 ⁺	-	-	-	-	+	+	+	-
L2 (HR0)	K18 ⁺	-	-	-	-	-	+	+	-
L3 (HR0)	K5 ⁺	-	-	-	+	-	+	+	-
L4 (HR1)	ER ⁺	+	-	-	-	-	+	+	-
L5 (HR1)	AR ⁺	-	+	-	-	-	+	+	-
L6 (HR1)	VDR ⁺	-	-	+	-	-	+	+	-
L7 (HR1)	K5 ⁺ VDR ⁺	-	-	+	+	-	+	+	-
L8 (HR2)	ER ⁺ AR ⁺	+	+	-	-	-	+	+	-
L9 (HR2)	ER ⁺ VDR ⁺	+	-	+	-	-	+	+	-
L10 (HR2)	AR ⁺ VDR ⁺	-	+	+	-	-	+	+	-
L11 (HR3)	ER ⁺ AR ⁺ VDR ⁺	+	+	+	-	-	+	+	-
Myoepithelial									
My1	CD10 ⁺	-	-	-	-	-	-	-	+
My2	K5 ⁺	-	-	-	+	-	-	-	+

IHC of normal breast sections from multiple donors ($n = 36$) with 14 different markers identified multiple normal breast cell subtypes. We grouped the 11 differentiation states in the luminal layer of human breast lobules (L1–L11) into HR0–HR3. All luminal cells expressed K7/8/18 and Cld-4. In the myoepithelial layer, all cells expressed CD10/SMA/p63, with 2 subtypes that were either K5/14/17⁻ (My1) or K5/14/17⁺ (My2).

scRNA Seq

García Solá, M., Stedile, M., Beckerman, I. *et al.* An Integrative Single-cell Transcriptomic Atlas of the Post-natal Mouse Mammary Gland Allows Discovery of New Developmental Trajectories in the Luminal Compartment. ***J Mammary Gland Biol Neoplasia*** **26**, 29–42 (2021). <https://doi.org/10.1007/s10911-021-09488-1>

Henry, S., Trousdell, M.C., Cyrill, S.L. *et al.* Characterization of Gene Expression Signatures for the Identification of Cellular Heterogeneity in the Developing Mammary Gland. ***J Mammary Gland Biol Neoplasia*** **26**, 43–66 (2021). <https://doi.org/10.1007/s10911-021-09486-3>




Fig. 2 Identification of mammary gland clusters based on their transcriptomic features. **(a)** UMAP plot showing the identification of the obtained cell clusters with putative mammary epithelial subpopulation by color code. **(b)** UMAP displaying relative expression levels of mammary subpopulation markers. **(c)** Dendrogram representing

cell clusters in hierarchical structure. Subpopulation distribution is indicated in each main branch. **(d)** Heatmap highlighting top 5 key marker genes used to infer the identities of clusters. The bars located above the figure indicate the associated cell subpopulations

García Solá, M., Stedile, M., Beckerman, I. *et al.* An Integrative Single-cell Transcriptomic Atlas of the Post-natal Mouse Mammary Gland Allows Discovery of New Developmental Trajectories in the Luminal Compartment. *J Mammary Gland Biol Neoplasia* **26**, 29–42 (2021). <https://doi.org/10.1007/s10911-021-09488-1>

SOLAR ET AL




Fig. 7 Diagram of MEC hierarchy from multipotent MaSC to the cell lineages determined by our sc-RNAseq integrative analysis. In each oval a few featured genes/proteins for each mammary cell sub-type are displayed. Small green ovals on the borders represent membrane proteins recognizable by antibodies suitable for FACS. Genes encoding intracellular proteins are indicated inside the “cells”. Arrows represent the general pseudotemporal trajectory of mammary cell

differentiation. The circle encompassing the luminal sub-populations indicates the cycling pattern of these cell types throughout post-natal life of female mice. Its colors depict the developmental process: progenitor cells of nulliparous females are at the beginning of our luminal pseudotime (purple), differentiated hormone-sensing and alveolar cells are intermediate stages (pale orange) and, at the end, luminal progenitors arise again in post-involution samples (yellow)

MOUSE-HUMAN MAMMARY EPITHELIUM sc-RNA-Seq





Journal of Mammary Gland Biology and Neoplasia (2021) 26:43–66
<https://doi.org/10.1007/s10911-021-09486-3>

ORIGINAL PAPER



Characterization of Gene Expression Signatures for the Identification of Cellular Heterogeneity in the Developing Mammary Gland

Samantha Henry^{1,2} · Marygrace C. Trousdell¹ · Samantha L. Cyril¹ · Yixin Zhao¹ · Mary. J. Felgman¹ · Julia M. Bouhuls³ · Dominik A. Aylard⁴ · Adam Slepel¹ · Camilla O. dos Santos¹





THE HUMAN BREAST

THE INTERMISSION

Table 2. Quantitative TDLU measures and breast cancer risk factors among 1,083 controls.

	<i>n</i>	Median TDLU span (μm)	TDLU counts/ mm^2	Median acini counts/TDLU	Median TDLU area (mm^2)
Age at BBD biopsy					
<40 years	244	0.56 (0.55-0.58)	0.48 (0.44-0.52)	7.56 (7.11-8.04)	0.11 (0.10-0.11)
40-49 years	431	0.52 (0.51-0.53)	0.49 (0.46-0.51)	7.52 (7.18-7.87)	0.09 (0.09-0.10)
50-59 years	272	0.47 (0.45-0.48)	0.43 (0.40-0.46)	5.32 (5.02-5.64)	0.07 (0.07-0.07)
≥ 60 years	136	0.46 (0.44-0.47)	0.38 (0.34-0.42)	4.33 (3.99-4.71)	0.07 (0.06-0.07)
<i>P</i>		<0.001	<0.001	<0.001	<0.001



TO BE CONTINUED NEXT WEEK WITH PATHOLOGY

?

Normal
mammary
tissue

Damage

Acute
inflammation

$T_H1 \gg T_H2$

Basement
membrane

Myoepithelial
cell

Ductal
epithelial cell

Cancer cell


Apoptotic cell

Dendritic cell


Chronic inflammation

1° tumor



Metastatic tumors



What goes wrong when cells go wrong?



NEXT WEEK



?